antibody

Mouse Anti-Human LAP/ TGF beta 1

MBS690382

0.1 mg

490 USD

monoclonal

mouse

nonconjugated

[(6G14)]

Antibody

Mouse Anti-Human LAP/ TGF beta 1

[LAP/ TGF beta 1]

[TGFB1; CED; LAP; DPD1; TGFB; TGFbeta]

[transforming growth factor beta-1; Transforming growth factor beta-1; transforming growth factor beta-1; TGF-beta-1; latency-associated peptide; prepro-transforming growth factor beta-1; transforming growth factor, beta 1]

[LAP/ TGF beta 1]

[TGFB1; TGFB1; CED; LAP; DPD1; TGFB; TGFbeta; TGFB; TGF-beta-1; LAP]

TGFB1_HUMAN

Monoclonal

IgG1

[(6G14)]

Mouse

Human

390

This antibody was selected for its ability to detect human LAP TGF beta 1

Protein G chromatography

Lyophilized

Lyophilized samples are stable for 2 years from date of receipt when stored at -70°C. Reconstituted antibody can be aliquoted and stored frozen at < -20°C for at least for six months without detectable loss of activity. Shipping: ships at RT or 4°C

Western Blot (WB), Neutr

WB: 1:500-1:1000. Neutralization of LAP-TGF bata 1 bioactivity: Yes

Preparation: This antibody was produced from a hybridoma (mouse myeloma fused with spleen cells from a mouse) immunized with human recombinant protein of LAP-TGFb1. Antigen: Recombinant human LAP TGF beta 1

Reconstitution: Reconstitute the antibody with 200 ul sterile PBS and the final concentration is 500 ug/ml. Reconstitution Buffer: PBS (sterile)

TGF-beta ligands are initially synthesized as precursor proteins that undergo proteolytic cleavage. The mature segments form active ligand dimers via a disulfide-rich core consisting of the characteristic 'cysteine knot '. TGF-beta signaling begins with binding to a complex of the accessory receptor betaglycan (also known as TGF-beta RIII) and a type II serine/threonine kinase receptor termed TGF-beta RII. This receptor then phosphorylates and activates a type I serine/threonine kinase receptor, either ALK-1 or TGF-beta RI (also called ALK-5). The activated type I receptor phosphorylates and activates Smad proteins that regulate transcription. Use of other signaling pathways that are Smad-independent allows for distinct actions observed in response to TGF-beta in different contexts.

63025222

NP_000651.3

NM_000660.5

P01137

44,341 Da

ACE Inhibitor Pathway (198763); ALK1 Signaling Events Pathway (137968); Adipogenesis Pathway (198832); Amoebiasis Pathway (167324); Amoebiasis Pathway (167191); Cardiac Progenitor Differentiation Pathway (712094); Cell Cycle Pathway (198811); Cell Cycle Pathway (83054); Cell Cycle Pathway (463); Chagas Disease (American Trypanosomiasis) Pathway (147809)

This gene encodes a member of the transforming growth factor beta (TGFB) family of cytokines, which are multifunctional peptides that regulate proliferation, differentiation, adhesion, migration, and other functions in many cell types. Many cells have TGFB receptors, and the protein positively and negatively regulates many other growth factors. The secreted protein is cleaved into a latency-associated peptide (LAP) and a mature TGFB1 peptide, and is found in either a latent form composed of a TGFB1 homodimer, a LAP homodimer, and a latent TGFB1-binding protein, or in an active form composed of a TGFB1 homodimer. The mature peptide may also form heterodimers with other TGFB family members. This gene is frequently upregulated in tumor cells, and mutations in this gene result in Camurati-Engelmann disease.[provided by RefSeq, Oct 2009]

Function: Multifunctional protein that controls proliferation, differentiation and other functions in many cell types. Many cells synthesize TGFB1 and have specific receptors for it. It positively and negatively regulates many other growth factors. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts. Subunit structure: Homodimer; disulfide-linked, or heterodimer with TGFB2 . By similarity. Secreted and stored as a biologically inactive form in the extracellular matrix in a 290 kDa complex (large latent TGF-beta1 complex) containing the TGFB1 homodimer, the latency-associated peptide (LAP), and the latent TGFB1 binding protein-1 (LTBP1). The complex without LTBP1 is known as the'small latent TGF-beta1 complex'. Dissociation of the TGFB1 from LAP is required for growth factor activation and biological activity. Release of the large latent TGF-beta1 complex from the extracellular matrix is carried out by the matrix metalloproteinase MMP3 . By similarity. May interact with THSD4; this interaction may lead to sequestration by FBN1 microfibril assembly and attenuation of TGFB signaling. Interacts with the serine proteases, HTRA1 and HTRA3: the interaction with either inhibits TGFB1-mediated signaling. The HTRA protease activity is required for this inhibition . By similarity. Latency-associated peptide interacts with NREP; the interaction results in a decrease in TGFB1 autoinduction . By similarity. Interacts with CD109, DPT and ASPN. Ref.12 Ref.15 Ref.17. Subcellular location: Secreted extracellular space extracellular matrix Ref.17. Tissue specificity: Highly expressed in bone. Abundantly expressed in articular cartilage and chondrocytes and is increased in osteoarthritis (OA). Colocalizes with ASPN in chondrocytes within OA lesions of articular cartilage. Ref.13 Ref.17. Induction: Activated in vitro at pH below 3.5 and over 12.5. Domain: The 'straitjacket' and 'arm' domains encircle the growth factor monomers and are fastened together by strong bonding between Lys-56 and Tyr-103/Tyr-104. Activation of TGF-beta1 requires the binding of integrin alpha-V to an RGD sequence in the prodomain and exertion of force on this domain, which is held in the extracellular matrix by latent TGF-beta binding proteins. The sheer physical force unfastens the straitjacket and releases the active growth factor dimer . By similarity. Post-translational modification: Glycosylated.The precursor is cleaved into mature TGF-beta-1 and LAP, which remains non-covalently linked to mature TGF-beta-1 rendering it inactive. Polymorphism: In post-menopausal Japanese women, the frequency of Leu-10 is higher in subjects with osteoporosis than in controls. Involvement in disease: Camurati-Engelmann disease (CE) [MIM:131300]: Autosomal dominant disorder characterized by hyperostosis and sclerosis of the diaphyses of long bones. The disease typically presents in early childhood with pain, muscular weakness and waddling gait, and in some cases other features such as exophthalmos, facial paralysis, hearing difficulties and loss of vision.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.23 Ref.24 Ref.26 Ref.27 Ref.28. Sequence similarities: Belongs to the TGF-beta family.

0.1 mg

490 USD